Testimony to Congress
The testimony of NIDA Director, Nora D. Volkow, M.D., and other senior staff before congress.
Hearing on Cannabis Policies for the New Decade
|
Chairwoman Eshoo, Ranking Member Burgess, and members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH)...
Marijuana and America’s Health: Questions and Issues for Policy Makers
|
Go to the Senate Caucus on International Narcotics Control site Chairman Cornyn, Co-Chairwoman Feinstein and members of the Caucus on International Narcotics Control, we appreciate the opportunity to share the...
Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives
|
Testimony by Dr. Nora Volkow, NIDA Director and others to the House Committee on Energy and Commerce
The Federal Response to the Opioid Crisis
|
Testimony by Dr. Francis Collins, NIH Director and others before the Senate Committee on Health, Education, Labor & Pensions
Research on the Use and Misuse of Fentanyl and Other Synthetic Opioids
|
Testimony by Wilson M. Compton, M.D., Deputy Director, National Institute on Drug Abuse before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
Fiscal Year 2017 Budget Request
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the House Subcommittee on Labor-HHS-Education Appropriations
Researching the Potential Medical Benefits and Risks of Marijuana
|
Testimony by Susan R.B. Weiss, Ph.D. - Director, Division of Extramural Research, National Institute on Drug Abuse, before the Senate Judiciary Committee, Subcommittee on Crime and Terrorism
What Science tells us About Opioid Abuse and Addiction
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the Senate Judiciary Committee